Verapamil for severe hyperkinetic movement disorders.
Identifieur interne : 004461 ( PubMed/Curation ); précédent : 004460; suivant : 004462Verapamil for severe hyperkinetic movement disorders.
Auteurs : F. Ovsiew [États-Unis] ; K J Meador ; K. SethiSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1998.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Calcium Channel Blockers, Verapamil.
- drug effects : Neurologic Examination.
- drug therapy : Hyperkinesis.
- Adult, Humans, Male.
Abstract
The use of verapamil in three cases of severe hyperkinetic movement disorders resulted in dramatic improvement in patients who had been refractory to many other treatments over a prolonged period. A videotape illustration of one of the patients is provided. The mechanism of action and evidence of efficacy of calcium-channel blockers for abnormal movements are discussed.
DOI: 10.1002/mds.870130224
PubMed: 9539352
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004461
Links to Exploration step
pubmed:9539352Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Verapamil for severe hyperkinetic movement disorders.</title><author><name sortKey="Ovsiew, F" sort="Ovsiew, F" uniqKey="Ovsiew F" first="F" last="Ovsiew">F. Ovsiew</name><affiliation wicri:level="1"><nlm:affiliation>University of Chicago, Illinois, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Chicago, Illinois</wicri:regionArea></affiliation></author><author><name sortKey="Meador, K J" sort="Meador, K J" uniqKey="Meador K" first="K J" last="Meador">K J Meador</name></author><author><name sortKey="Sethi, K" sort="Sethi, K" uniqKey="Sethi K" first="K" last="Sethi">K. Sethi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9539352</idno><idno type="pmid">9539352</idno><idno type="doi">10.1002/mds.870130224</idno><idno type="wicri:Area/PubMed/Corpus">004461</idno><idno type="wicri:Area/PubMed/Curation">004461</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Verapamil for severe hyperkinetic movement disorders.</title><author><name sortKey="Ovsiew, F" sort="Ovsiew, F" uniqKey="Ovsiew F" first="F" last="Ovsiew">F. Ovsiew</name><affiliation wicri:level="1"><nlm:affiliation>University of Chicago, Illinois, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Chicago, Illinois</wicri:regionArea></affiliation></author><author><name sortKey="Meador, K J" sort="Meador, K J" uniqKey="Meador K" first="K J" last="Meador">K J Meador</name></author><author><name sortKey="Sethi, K" sort="Sethi, K" uniqKey="Sethi K" first="K" last="Sethi">K. Sethi</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Calcium Channel Blockers (therapeutic use)</term><term>Humans</term><term>Hyperkinesis (drug therapy)</term><term>Male</term><term>Neurologic Examination (drug effects)</term><term>Verapamil (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Calcium Channel Blockers</term><term>Verapamil</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hyperkinesis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Humans</term><term>Male</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The use of verapamil in three cases of severe hyperkinetic movement disorders resulted in dramatic improvement in patients who had been refractory to many other treatments over a prolonged period. A videotape illustration of one of the patients is provided. The mechanism of action and evidence of efficacy of calcium-channel blockers for abnormal movements are discussed.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9539352</PMID><DateCreated><Year>1998</Year><Month>06</Month><Day>15</Day></DateCreated><DateCompleted><Year>1998</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>1998</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Verapamil for severe hyperkinetic movement disorders.</ArticleTitle><Pagination><MedlinePgn>341-4</MedlinePgn></Pagination><Abstract><AbstractText>The use of verapamil in three cases of severe hyperkinetic movement disorders resulted in dramatic improvement in patients who had been refractory to many other treatments over a prolonged period. A videotape illustration of one of the patients is provided. The mechanism of action and evidence of efficacy of calcium-channel blockers for abnormal movements are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ovsiew</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University of Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meador</LastName><ForeName>K J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Sethi</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>CJ0O37KU29</RegistryNumber><NameOfSubstance UI="D014700">Verapamil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002121">Calcium Channel Blockers</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006948">Hyperkinesis</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014700">Verapamil</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>4</Month><Day>16</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>4</Month><Day>16</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9539352</ArticleId><ArticleId IdType="doi">10.1002/mds.870130224</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004461 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004461 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:9539352
|texte= Verapamil for severe hyperkinetic movement disorders.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:9539352" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |